2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 163

Ultrasonographic Assessment Covers Clinical Examination in the Localization of Ankle Pathology in Rheumatoid Arthritis
Abstract Number: 436

Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According to Different Remission Criteria: Should We Insist on Achieving Boolean Remission?
Abstract Number: 161

Ultrasonographic Evaluation of Rheumatoid Hand: Hand Disability and Disease Activity Correlation
Abstract Number: 177

Ultrasonographic Joint Evaluation in Daily Practice: What Is Its Contribution to Clinical Assessment?
Abstract Number: 169

Ultrasonographic Signs of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients Who Are Treated to Target
Abstract Number: 162

Ultrasonography Versus Clinical Examination in Early DMARD-Naïve Rheumatoid Arthritis – a Comparative Study of Synovitis on the Individual Joint Level
Abstract Number: 441

Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis
Abstract Number: 927

Ultrasound Assessment of Heel Entheses in Spondyloarthritis Patients: A Comparative Study with Radiography and Magnetic Resonance Imaging
Abstract Number: 168

Ultrasound Evaluation of the Efficacy of Biologic and Targeted Synthetic Dmards Toward Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort in Japan
Abstract Number: 190

Ultrasound Imaging with Elastography for the Medical Treatment of Dupuytren’s Contracture
Abstract Number: 180

Ultrasound Quantification of Fluid Shifts in the Knees of Arthritis Patients before and after Inflation of a Pneumatic Compressive Device
Abstract Number: 2591

Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients
Abstract Number: 158

Ultrasound Score of Dominant Hand in Patients with Rheumatoid Arthritis Correlates with DAS28CRP, CDAI and SDAI but Not RAPID-3
Abstract Number: 1496

Uncovering and Addressing Issues Related to Medication Adherence Among Patients with Rheumatic Diseases: A Patient Navigator Pilot Program
Abstract Number: 2061

Uncovering Crohn’s Disease in Patients with Spondyloarthropathies Using Videocapsule Endoscopy
Abstract Number: 3117

Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study
Abstract Number: 2324

Understanding the Importance of a Patient’s Role in the Management of RA: Results from a Patient-Based Survey
Abstract Number: 1997

Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
Abstract Number: 706

Undifferentiated Spondylarthritis May More Frequent in Japanese
Abstract Number: 1794

Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients
Abstract Number: 1030

Unwanted Variations in Rheumatology Clinic Rooming: A Time Study Tool and Analysis
Abstract Number: 942

Update in the Management of Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs Following Coccidioidomycosis
Abstract Number: 412

Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 50 Patients at First Assessment. Www.Juvenile-Scleroderma.Com
Abstract Number: 819

Upregulation of Complement C3 and Alpha-2-Macroglobulin in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 1273

Uptake of the First Biosimilar Infliximab Since Its Approval in South Korea
Abstract Number: 229

Uric Acid and Incident Dementia over 10 Years
Abstract Number: 231

Uric Acid Levels Predict Mortality in Women
Abstract Number: 2342

Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Abstract Number: 2070

Urinary Biomarker Based “a-RAIL”� Study in Adults with Lupus Nephritis
Abstract Number: 385

Urinary Cell-Free Microrna’s As Biomarkers of Lupus Nephritis in Children
Abstract Number: 718

Urinary MBL : A Promising Biomarker for Predicting Flare in Lupus Nephritis
Abstract Number: 2071

Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study
Abstract Number: 2905

Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis
Abstract Number: 716

Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
Abstract Number: 1277

US Adult Rheumatologists Perspective on the Transition Process for Young Adults with Rheumatic Conditions
Abstract Number: 442

Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Abstract Number: 1200

Use of Focus Groups and Patient Partners to Revise an Internet Self-Management Program
Abstract Number: 2484

Use of Lean Six Sigma Methodology to Improve Time to Scheduling for New Patient Referrals to Rheumatology
Abstract Number: 2365

Use of Long Term Subscutaneous Immunoglobulins in Inflammatory Myopathies: A Retrospective Analysis of 19 Patients
Abstract Number: 1003

Use of Nsaids Correlates with the Risk of Venous Thromboembolism in Knee OA Patients: A UK Population-Based Case-Control Study
Abstract Number: 2415

Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States
Abstract Number: 428

Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry
Abstract Number: 263

Use of Serum Ferritin and Heme Oxygenase 1 for the Diagnosis of Adult-Onset Still’s Disease: A Preliminary Report of Multicenter Study
Abstract Number: 1012

Use of Social Media By Rheumatology Fellows in North America
Abstract Number: 47

Use of Social Media Data for Comparative Effectiveness and Safety Research: An Example from Rheumatoid Arthritis
Abstract Number: 577

Use of Subcutaneous MTX Does Not Prolong the Use of Traditional DMARD in Multi-DMARD Regimens and Has Insignificant Differences in Liver Enzymes Abnormalities When Compared with Oral MTX in Patients with Rheumatoid Arthritis: A Veteran Affairs Administrative Database Study
Abstract Number: 450

Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Abstract Number: 631

Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients
Abstract Number: 156

Usefulness of the Stricter Remission Criteria for Assessing the Absence of Subclinical Activity in Rheumatoid Arthritis
Abstract Number: 2950

Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus
Abstract Number: 3229

Using Exome Sequencing to Identify Novel Genetic Associations with Granulomatosis with Polyangiitis Susceptibility
Abstract Number: 2440

Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis
Abstract Number: 2161

Ustekinumab for the Treatment of Refractory Giant Cell Arteritis
Abstract Number: 636

Utility of IgA Anti-Alpha-Fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies As Substitute Immunological Criterion for Sjögren’s Syndrome
Abstract Number: 3209

Utility of Power Doppler Ultrasound-Detected Synovitis for the Prediction of Short Term Flare in Psoriatic Arthritis Patients in Clinical Remission
Abstract Number: 153

Utility of Ultrasound Synovitis Assessment As a Predictor of Flares in Clinically Inactive Joints
Abstract Number: 2904

Utility of Untimed Single Urine Protein/Creatinine Ratio As a Substitute for the 24 Hour Proteinuria for the Assessment of Proteinuria in Systemic Lupus Erythematosus
Abstract Number: 2455

Utilization and Education of Nurse Practitioners in Pediatric Rheumatology
Abstract Number: 1272

Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By SLE Patients: A 13 Year Population Health Study
Abstract Number: 2528

Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases
Abstract Number: 1268

Utilization of Viscosupplementation: 2011 – 2013
Abstract Number: 56

Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].